UMIN-CTR Clinical Trial

BACK TOP
UMIN-CTR English Home Glossary (Simple) FAQ Search clinical trials

Name:
UMIN ID:

Recruitment status Completed
Unique ID issued by UMIN UMIN000000732
Receipt No. R000000880
Scientific Title Multicenter study of combination therapy using mizoribine, cyclosporin, basiliximab and steroids in kidney transplantation.
Date of disclosure of the study information 2007/06/10
Last modified on 2015/01/07

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information
Public title Multicenter study of combination therapy using mizoribine, cyclosporin, basiliximab and steroids in kidney transplantation.
Acronym Multicenter study of combination therapy using mizoribine, cyclosporin, basiliximab and steroids in kidney transplantation.
Scientific Title Multicenter study of combination therapy using mizoribine, cyclosporin, basiliximab and steroids in kidney transplantation.
Scientific Title:Acronym Multicenter study of combination therapy using mizoribine, cyclosporin, basiliximab and steroids in kidney transplantation.
Region
Japan

Condition
Condition Kidney transplantation
Classification by specialty
Urology
Classification by malignancy Others
Genomic information NO

Objectives
Narrative objectives1 To Compare the clinical outcome of mizoribine(MZ) and mycophenolate mofetil(MMF). We will perform the study of combination therapy in kidney transplantation, combined with MZ, cyclosporine(CyA), basiliximab and steroids, in compareson with historyical data with MMF, CyA, basiliximab and steroids.
Basic objectives2 Safety,Efficacy
Basic objectives -Others
Trial characteristics_1
Trial characteristics_2
Developmental phase

Assessment
Primary outcomes Incidence of virus infection
Key secondary outcomes Rejection reactions (incidence, types, severity), patient survival rate, graft suvival rate, incidence of adverse events / abnormalities in the laboratory values.

Base
Study type Interventional

Study design
Basic design Single arm
Randomization Non-randomized
Randomization unit
Blinding Open -but assessor(s) are blinded
Control Historical
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment

Intervention
No. of arms 1
Purpose of intervention Treatment
Type of intervention
Medicine
Interventions/Control_1 cyclosporinbasiliximab + steroids + mizoribine
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10

Eligibility
Age-lower limit
2 years-old <=
Age-upper limit
70 years-old >=
Gender Male and Female
Key inclusion criteria 1.living donor kidney transplantation. 2.Gender free, any case of uremia. 3.Aged 2 years to 70 years. 4.ABO compatible (including semi-compatible)
The patient or whose family has submitted (if the patient is showing disturbance of consciousness or decreased ability to understand) written consent forms based on their free choice once adequate information and understandings are obtained regarding the study upon the participation.
Key exclusion criteria 1.The patient who has a history of hypersensitivity against components of either one of the following drugs: Bredinin tablet, Neoral or Simulect. 2.The patient who is pregnant or a female patient who is expecting to become pregnant. 3.The patients who showed a positive result with cross match test. 4.The patient who recived ABO incompatible donor. 5.The patient with whom the physician-in-charge considered inappropriate as a subject of this study.
Target sample size 70

Research contact person
Name of lead principal investigator
1st name
Middle name
Last name Akira Hasegawa
Organization Toho University
Division name School of Medicine
Zip code
Address 6-11-1 Omori-nishi Ota-ku,Tokyo,Japan
TEL
Email

Public contact
Name of contact person
1st name
Middle name
Last name
Organization MNKT Forum
Division name Keio University Department of Urolgy
Zip code
Address
TEL 03-5919-3825
Homepage URL
Email

Sponsor
Institute MNKT Forum
Institute
Department

Funding Source
Organization Self funding
Organization
Division
Category of Funding Organization Self funding
Nationality of Funding Organization

Other related organizations
Co-sponsor
Name of secondary funder(s)

IRB Contact (For public release)
Organization
Address
Tel
Email

Secondary IDs
Secondary IDs NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW

Institutions
Institutions

Other administrative information
Date of disclosure of the study information
2007 Year 06 Month 10 Day

Related information
URL releasing protocol
Publication of results Unpublished

Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description

Progress
Recruitment status Completed
Date of protocol fixation
2006 Year 06 Month 02 Day
Date of IRB
Anticipated trial start date
2006 Year 06 Month 01 Day
Last follow-up date
2013 Year 05 Month 01 Day
Date of closure to data entry
Date trial data considered complete
Date analysis concluded

Other
Other related information

Management information
Registered date
2007 Year 06 Month 05 Day
Last modified on
2015 Year 01 Month 07 Day


Link to view the page
URL(English) https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000000880

Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name


Contact us.